ruxolitinib

Disorders of Depigmentation: Focus on Vitiligo
vitiligo
by Emily Murphy, MD on
At the 2023 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of vitiligo from the renowned researcher and clinician, Dr.  John Harris, Professor and Chair of Dermatology at the University of Massachusetts. When a new patient with vitiligo presents to my clinic, I always pull out my phone to consult Dr. Harris’ treatment protocol – I am sure I …
How to Diagnose and Treat Hypopigmentation with Dr. Hamzavi
hypopigmentation
by NEXT STEPS IN DERM TEAM on
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Iltefat Hamzavi, dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Dr. Hamzavi addresses how to diagnose and treat hypopigmentation, a catch-all for pigmentary conditions where the pigment is not too dark or complete …
Skin Enzymes – Friday Pop Quiz 8/19/2022
by NEXT STEPS IN DERM TEAM on
The medication that the FDA recently approved for the treatment of this condition inhibits the same enzymes as which of the following? A. Ruxolitinib B. Abrocitinib C. Apremilast D. Adalimumab E. Tofacitinib To find out the correct answer and read the explanation, click here.    Brought to you by our brand partner Derm In-Review.  A product of SanovaWorks. …
Dermatology Industry Joins Fight Against COVID-19
Dermatology industry joins fight against covid-19
by Allison Sit on
EPI Health has graciously supported the COVID-19 News and Resource Center. Companies in the dermatology industry are playing a role in the fight against COVID-19. From researching possible treatments and vaccines to modifying production lines for essential products, the following is a listing of dermatology companies and their COVID-19 efforts: AbbVie is researching whether its drug KALETRA …